Lipocine Inc. — Q2 2021 Form 10-Q
Reporting period: Three and six months ended June 30, 2021; filed August 5, 2021. Lipocine is a clinical-stage biopharmaceutical company developing oral therapies. It reported no product sales revenue and remains dependent on financing and licensing activities.
Financial performance and position
- Revenue: No product revenue was reported. The filing says the company has not generated product sales revenue and does not expect to do so until a product receives regulatory approval.
- Q2 results: Operating expenses were $3.0 million, down from $4.2 million in Q2 2020. Net loss was $6.8 million, compared with $6.4 million; basic and diluted loss per share was $0.08 versus $0.13. The Q2 2021 loss included a $4.0 million Clarus settlement expense, partly offset by a $221,000 non-cash gain on warrant remeasurement.
- First-half results: Operating expenses were $6.1 million versus $8.8 million in 2020. Net loss was $10.2 million versus $12.1 million; loss per share was $0.12 versus $0.27. Lower research, administrative and warrant-related expenses were partly offset by the $4.0 million settlement charge.
- Margins: Not meaningful because the company reported no product revenue.
- Cash flow: First-half operating cash use was $6.4 million, compared with $7.5 million in 2020. Investing cash use was $35.4 million, mainly purchases of marketable securities; financing provided $28.6 million, principally from equity offerings.
- Liquidity: At June 30, unrestricted cash, cash equivalents and marketable securities totaled $46.6 million, including $11.0 million cash and $35.7 million marketable securities. Current assets were $47.2 million and current liabilities $8.8 million. Management expected existing resources to fund planned operations through at least June 30, 2022, subject to assumptions and operating plans.
- Debt and settlement obligations: Debt was $4.0 million, classified as current, with the SVB loan maturing June 1, 2022 and a $650,000 final payment charge due at maturity. The $4.0 million Clarus settlement is payable $2.5 million immediately, $1.0 million in July 2022 and $500,000 in July 2023.
Material changes versus the prior comparable period
- First-half operating expenses declined by $2.7 million, primarily due to lower LPCN 1144 clinical-trial and legal costs and reduced stock-based compensation.
- First-half net loss improved by $2.0 million despite the new settlement charge, partly because the 2020 period included a larger non-cash warrant remeasurement loss.
- Unrestricted cash, cash equivalents and marketable securities increased from $19.7 million at year-end 2020 to $46.6 million, supported by the January 2021 stock offering and ATM sales. Common shares outstanding increased from 70.0 million at December 31, 2020 to 88.3 million at June 30, 2021.
- The company released the $5.0 million cash collateral previously required under its SVB loan after amending the agreement in February 2021.
Outlook, commentary and risks
- TLANDO: The FDA granted tentative approval in December 2020, but final approval and U.S. marketing are barred until the JATENZO exclusivity period expires March 27, 2022. The company is considering out-licensing, self-commercialization or a risk-sharing partner. Required post-marketing studies include a label-understanding study and a one-year study of adrenal insufficiency.
- Pipeline: LPCN 1144’s Phase 2 LiFT study reported positive 12-week liver-fat and liver-injury-marker results; 36-week biopsy data were expected in August 2021. LPCN 1154’s FDA-cleared development program included a PK study, with a proof-of-concept study planned. The first LPCN 1148 subject was expected in Q4 2021. Further development of TLANDO XR and LPCN 1107 depends on additional study work and FDA feedback.
- Funding: Management expects continuing operating losses and says additional capital will be needed at some point, through equity or debt financing or licensing. Financing may be unavailable or dilutive; absent adequate funding, the company may reduce, delay or suspend development and commercialization activities. Additional studies or TLANDO launch preparation could consume cash sooner than projected.
- Litigation: In May 2021, a court found asserted Lipocine patent claims against Clarus invalid. The July 2021 global settlement resolved the patent litigation and related interference, with no future royalties between the parties. A separate shareholder class action remains pending; the company has not accrued a loss because it considers an outcome not probable and cannot estimate any loss. Insurance retention is $1.25 million.
- Other risks: TLANDO faces competing testosterone therapies; clinical and regulatory outcomes remain uncertain. The company also disclosed potential dilution, volatile share price, reliance on external financing and a need to preserve sufficient authorized shares. It reported effective disclosure controls as of June 30, 2021 and no material change in internal control over financial reporting.
Important facts for investors to verify
- Whether TLANDO receives final FDA approval after March 27, 2022, and the timing, cost and chosen commercialization strategy.
- Whether LPCN 1144’s 36-week biopsy results support continued development, and whether planned LPCN 1148 and LPCN 1154 studies proceed on schedule.
- Cash runway assumptions behind management’s estimate through June 30, 2022, including settlement payments, clinical spending and any TLANDO launch preparation.
- Availability and terms of future financing, including potential dilution under the ATM facility; $41.2 million remained available under the Sales Agreement at June 30, 2021.
- Repayment of the SVB loan and final payment charge by maturity, and the status and potential cost of the shareholder class action.